India’s drug regulators order Sun Pharma to stop producing ophthalmic (eye-care) medicines at an Assam plant after quality compliance concerns. The action is part of stepped-up scrutiny of domestic drug manufacturing practices.
Context comes from broader concerns about drug quality, which have been in the spotlight in recent years in both India and abroad. Earlier incidents involving cough syrups have been reported as linked to child deaths, including cases in countries such as Gambia and Uzbekistan. In this wider environment, regulators are requiring stronger checks and documentation from manufacturers. Across the coverage, outlets focus on the halt at Sun Pharma’s eye-care drug facility and the compliance steps the company must complete before production can resume, with emphasis on regulators’ heightened enforcement.
